Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Japanese firms ASKA Pharmaceutical (Aska) and Takeda Pharmaceutical (Takeda) have entered into a distribution agreement for Candesartan 'ASKA' (candesartan cilexetil), a drug indicated for the treatment of hypertension.
Subscribe to our email newsletter
Candesartan ASKA is an authorized generic (AG) of Blopress (candesartan cilexetil), which Takeda has licensed the patent to Aska.
Aska had received approval for the drug from the Japanese Ministry of Health, Labour and Welfare in February 2014, and is currently applying for listing on the National Health Insurance (NHI) Price List for June 2014.
As part of the agreement, Aska will launch and promote Candesartan ‘ASKA’ to healthcare professionals after it is listed on the NHI Price list.
Takeda will buy the drug from Aska, and will be responsible for its distribution to wholesalers.
In October 2013, Aska had formed a Generics Business Division, which will work jointly with the existing Pharma Business Division to promote the pharmaceutical sales business.
The launch of Candesartan ‘ASKA’ will expand Aska’s product lineup and strengthen its presence in the generics arena.
The launch will also allow Aska to provide healthcare professionals and patients with an AG that contains identical active pharmaceutical ingredients, additives, and production method as Blopress.
Both the firms will strengthen their contributions to the treatment of hypertension through Blopress and will continue to provide pharmaceutical products to meet various medical needs.
Takeda will continue to collect clinical data results of Blopress and will mainly focus on safety evaluation and provide the information to healthcare professionals.
Image: Takeda will buy Candesartan ASKA from Aska and will be responsible for its distribution to wholesalers. Photo: courtesy of winnond